QuidelOrtho Corporation (QDEL) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call provides mixed signals: while revenue and EBITDA guidance are positive, free cash flow fell short due to timing issues. The Q&A reveals sustainable growth in the Lab segment and strategic partnerships, but also highlights uncertainties in respiratory revenue and flat gross margins. The market cap indicates a moderate reaction, leading to a neutral prediction for stock price movement.
Key Financial Performance
Cost Savings Generated $140 million in cost savings, expanded adjusted EBITDA margins to the low 20s, and increased financial flexibility. This was achieved through realignment of cost structure and improved execution rigor.
Revenue (Q4 2025) $724 million, a 2% year-over-year increase. Growth was driven by a 7% increase in Non-respiratory revenue (excluding Donor Screening) and strong performance in the Labs business.
Revenue (Full Year 2025) $2.73 billion, with Non-respiratory revenue growing 5% year-over-year. Labs business grew 6% and represented 55% of total company revenue.
Respiratory Revenue $402 million for the full year, declined 14% in Q4 and 20% for the full year due to lower COVID testing. However, flu revenue grew 6% in Q4 and 3% for the full year.
Operating Expenses Decreased by 5% year-over-year due to company-wide cost savings initiatives.
Adjusted EBITDA Margin 22% for the full year, representing a 240 basis point improvement over the prior year.
Adjusted Gross Profit Margin (Q4 2025) 44.9%, a decline of 190 basis points year-over-year due to tariffs, higher instrument placements, and product mix.
Adjusted Gross Profit Margin (Full Year 2025) 47.4%, a 40 basis point increase year-over-year driven by cost mitigations, offset by tariff impacts.
Adjusted Diluted EPS $0.46 in Q4 and $2.12 for the full year, representing 15% year-over-year growth.
Free Cash Flow $87 million in Q4. For the full year, recurring free cash flow was $100 million, falling short of the 25% conversion goal due to ERP system issues and late Q4 sales collections.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
FDA clearance for high-sensitivity troponin I assay: Received FDA clearance for high-sensitivity troponin I assay on the VITROS platform, with U.S. shipments starting soon. This supports clinical decision-making in emergency and acute care settings.
FDA clearance for ID MTS Direct Antiglobulin Test Card: Received FDA clearance for the ID MTS Direct Antiglobulin Test Card on the Vision immunohematology platform, offering a complete gel-based DAT solution.
Launch of QuidelOrtho Results Manager: Introduced a new informatics middleware solution for laboratory workflow management, starting with the Labs business, with plans to expand to other portfolios.
Upcoming product launches in 2026: Plans to launch VITROS 450, a modernized system for key OUS markets, and new immunoassay platforms with over 70 assays for OUS markets. Also preparing for the commercialization of the LEX molecular diagnostics platform.
Regional growth performance: Strong growth in Latin America (17% in Q4, 18% for the year) and Japan/Asia Pacific (4% in Q4, 6% for the year). North America and Europe showed mixed results, with North America up 4% in Q4 but down 2% for the year, and Europe flat in Q4 but up 4% for the year.
China market performance: China grew 5% in Q4 and 3% for the full year, indicating steady growth.
Cost savings initiatives: Achieved $140 million in cost savings, reduced operating expenses by 5%, and improved adjusted EBITDA margin to 22%, a 240 basis point increase year-over-year.
R&D reorganization: Upgraded talent, modernized processes, and prioritized impactful programs, resulting in a stronger and more productive R&D organization.
Focus on higher growth markets: Sharpened focus on prioritizing higher growth markets and selective capital deployment.
Leadership transition: Announced CFO Joe Busky's retirement in June 2026, with a search for his successor underway.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
COVID-19 and Respiratory Revenue Decline: The company experienced a decline in respiratory revenue, including COVID-19 testing, which decreased by 14% in Q4 and 20% for the full year. This decline impacts overall revenue and highlights the challenge of reduced demand for COVID-related products.
Gross Profit Margin Pressure: The adjusted gross profit margin declined by 190 basis points in Q4 due to tariffs, higher instrument placements, and product mix. This indicates challenges in maintaining profitability amidst changing cost structures and market conditions.
ERP System Issues: ERP system issues led to a $15 million to $20 million impact on free cash flow, contributing to the company falling short of its 25% free cash flow conversion goal. This operational challenge affects financial performance and efficiency.
Goodwill Impairment Charge: A significant $701 million non-cash goodwill impairment charge was recorded in Q3, reflecting post-pandemic market valuations. While it does not impact cash or operations directly, it indicates challenges in maintaining asset valuations.
Debt and Leverage Concerns: The net debt to adjusted EBITDA ratio was 4.2x at the end of the year, above the company's target. This higher leverage poses financial risks and limits flexibility in capital allocation.
China Market Growth Challenges: China's growth was limited to 5% in Q4 and 3% for the full year, indicating challenges in achieving higher growth in this key market.
Discontinuation of Savanna Business: The planned discontinuation of the Savanna business and the acquisition of LEX Diagnostics is expected to result in minimal revenue contribution from LEX in 2026, creating a short-term revenue gap.
Tariff Impacts: Tariffs contributed to a decline in gross profit margin, adding to cost pressures and impacting profitability.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Expectations: Full year 2026 reported revenues are expected to be between $2.7 billion and $2.9 billion, with quarterly revenue phasing similar to 2025.
Business Segment Performance: The Labs business is expected to grow in the mid-single digits, immunohematology to grow in the low single digits, and the U.S. Donor Screening business wind down to be substantially complete by midyear 2026. Point of care growth is assumed to be relatively flat at the midpoint of guidance, based on a typical flu season. Triage cardiac growth is expected to continue in the high single digits. Molecular growth is expected to decline slightly due to the discontinuation of the Savanna business, with minimal revenue contribution from LEX Diagnostics in 2026.
Adjusted EBITDA and Margins: Adjusted EBITDA is anticipated to be between $630 million and $670 million, equating to an adjusted EBITDA margin of approximately 23.3%, a 130 basis point improvement compared to full year 2025.
Free Cash Flow: Strong free cash flow is expected between $120 million and $160 million, factoring in $50 million to $60 million in one-time cash use associated with facility consolidation and procurement cost savings initiatives.
Capital Expenditures: CapEx is expected to be between $150 million and $170 million for the full year 2026.
Debt and Leverage: Net debt leverage is expected to be approximately 3.8x by the end of 2026, progressing towards the goal of between 2.5x and 3.5x.
Product Launches and Innovations: New products expected to launch in 2026 include the VITROS 450 platform, new innovative immunoassay platforms for OUS markets, and the LEX molecular diagnostics platform. These launches are anticipated to drive customer value and expand assay menus.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Why did the free cash flow guide come in lower than expected for the quarter?
A:The Q4 cash flow came in at 17% of full-year EBITDA versus the expected 25% due to two main reasons: $15-$20 million of system-related AR collections spilled into January, and $20 million of late revenue in Q4 was collected in January. This $40-$45 million timing difference caused the shortfall, but the cash has already been collected in Q1.
Q:How sustainable are the strong growth trends in the Lab segment?
A:The Lab segment showed 7% growth for the quarter and 6% for the year. Management believes the growth is sustainable due to strong market positions, high renewal rates, underpenetration in immunoassay, and opportunities in low OUS market penetration. They also highlighted new product introductions like the VITRO 450 and partnerships to strengthen competitiveness.
Q:What is the growth assumption for China in the guide for the year?
A:The growth assumption for China is low single-digit growth in 2026, consistent with 2025.
Q:Is there any update on the dry slide and VBP in China?
A:There is no new update. The Jiangxi provincial HSA announced plans to explore a nationalized VBP program for dry chemistry test strips in 2026, but no detailed proposal or product inclusion details have been provided. If included, the estimated impact would be 0.5%-1% of total company revenue, which the company plans to offset elsewhere.
Q:What is the status of the Sofia combo product (ABC) and its contribution to revenue?
A:The Sofia combo product continues to perform well, contributing over 50% of total flu revenue consistently for the past two years. Management could not confirm if there was a transition from standalone COVID tests to the combo product.
Q:What are the assumptions behind the EPS guidance range for 2026?
A:The wide EPS guidance range is due to uncertainty in the respiratory business. The midpoint assumes $50-$55 million in respiratory revenue, while the low and high ends assume $40-$45 million and $60-$65 million, respectively. Depreciation and amortization are expected to increase by $20 million year-over-year, impacting adjusted EPS by $0.21-$0.22.
Q:What are the future areas of focus for cost savings and margin improvement?
A:Management is focused on achieving a 25%+ EBIT margin through initiatives like exiting the Donor Screening business, optimizing manufacturing footprints, improving regional profitability, and leveraging higher-margin products like immunoassay and LEX. They also plan to optimize staffing and add new menu items to existing products.
Q:What is the gross margin outlook for 2026?
A:Gross margins are expected to remain relatively flat in 2026 due to tariff impacts, product mix, and LEX dilution. Direct procurement initiatives are expected to contribute more significantly to margin improvement in 2027 and beyond.
Q:What is the status of the LEX platform and its expected impact?
A:The LEX platform is undergoing FDA review, which is progressing as planned. Management expects molecular margins from LEX to benefit gross margins over time, but no immediate revenue impact is anticipated.
Q:What is the purpose of the new OUS partnership?
A:The partnership aims to strengthen the company's portfolio in OUS markets by addressing tender gaps and providing higher-throughput systems. This will help the company compete in lower-cost, lower-volume segments and improve its competitive position in OUS markets.
Q:What is the outlook for free cash flow in 2026 and beyond?
A:The midpoint of the 2026 free cash flow guide is $140 million, with $50-$60 million in onetime cash outlays. Recurring free cash flow is expected to be around $200 million. Onetime cash outlays are expected to decrease further in 2027, with free cash flow expanding as EBITDA margins improve and working capital initiatives are implemented.
Q:What is the potential impact of the high-sensitivity troponin assay on revenue?
A:The high-sensitivity troponin assay is not expected to have a significant short-term revenue impact but will help the company compete better in higher-volume segments over the long term. The assay is already contributing to growth outside the U.S., and the company is exploring ways to commercialize it in the U.S.
Q:Review of Unclear Management Responses
A:Management avoided providing a direct answer on whether there was a transition from standalone COVID tests to the Sofia combo product. Additionally, they did not provide specific details on the timeline for achieving the 50% free cash flow conversion target or the exact financial impact of the new OUS partnership.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
DAT
FDA clearance
IR page
LEX
Manager
Non Labs
PCR
President Investor
QuidelOrtho
Siegrist
VITROS platform
Vice President
afternoon today
care
chemistry
cost saving
culture
experience
informatics
information IR
journey
menu assay
offering
platform market
portfolio
progress RD
quality
review
rigor
sensitivity
stage
successor
system VITROS
talent
team
transition
QDEL Transcript
QuidelOrtho Corporation (QDEL) Q4 2025 Earnings Call Transcript
Unknown2-11
The earnings call provides mixed signals: while revenue and EBITDA guidance are positive, free cash flow fell short due to timing issues. The Q&A reveals sustainable growth in the Lab segment and strategic partnerships, but also highlights uncertainties in respiratory revenue and flat gross margins. The market cap indicates a moderate reaction, leading to a neutral prediction for stock price movement.
QuidelOrtho Corporation (QDEL) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Neutral12-3
Curaleaf Holdings, Inc. (CURA:CA) Q3 2025 Earnings Call Transcript
Unknown11-6
The earnings call presents mixed signals. Positive aspects include international growth, improved gross margins, and cash flow generation. However, declines in retail revenue, net loss, and unclear management responses on future margin expansion and regulatory impacts are concerns. The market cap suggests moderate volatility, leading to a neutral stock price prediction.
QuidelOrtho Corporation (QDEL) Q3 2025 Earnings Call Transcript
Unknown11-6
The earnings call presents mixed signals. Positive aspects include a significant increase in adjusted EBITDA and EPS, and successful cost-saving measures. However, negative factors such as a decrease in gross profit margin, negative free cash flow, and unclear timelines for new product developments temper the outlook. The Q&A highlights competitive wins and strategic geographic expansion, but also exposes risks like lower Q4 margins and technical challenges. Given the market cap, these mixed factors suggest a neutral stock price movement within the next two weeks.
QDEL Slides
QDEL Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
